Document Classification

Section Type: METHODS

Text: In a multicenter randomized double-blind placebo-controlled trial (Alpha-Lipoic Acid in Diabetic Neuropathy [ALADIN] III Study), 509 outpatients were randomly assigned to sequential treatment with 600 mg alpha-lipoic acid once daily intravenously for 3 weeks, followed by 600 mg alpha-lipoic acid three times a day orally for 6 months (A-A ; n = 167) ; 600 mg alpha-lipoic acid once daily intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (A-P ; n = 174) ; and placebo once daily intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (P-P ; n = 168).